Patents by Inventor Nicola Klein

Nicola Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
    Patent number: 6420338
    Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: July 16, 2002
    Assignee: New York University Medical Center
    Inventors: Robert J. Schneider, Nicola Klein
  • Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
    Publication number: 20020045191
    Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.
    Type: Application
    Filed: September 17, 2001
    Publication date: April 18, 2002
    Inventors: Robert J. Schneider, Nicola Klein